Bethacol25 mg

Bethacol 25 mg is a cholinergic (parasympathomimetic) agent used to stimulate the smooth muscle of the urinary bladder and gastrointestinal tract. Its evidence-based uses are:

• Established/approved use: Treatment of acute non-obstructive (functional) urinary retention, particularly postoperative and postpartum urinary retention, when catheterization is undesirable or contraindicated.
• Established/approved use: Treatment of urinary retention associated with neurogenic atony of the bladder (e.g., in diabetic bladder disease) with retention.
• Off-label/limited use (not routinely recommended): Bethacol 25 mg has in the past been tried for gastroesophageal reflux and gastroparesis-type symptoms to promote gastric and esophageal motility, but this use is not well supported by current evidence and is not a standard indication.

Bethacol 25 mg is only effective for non-obstructive retention; it must never be used when a mechanical obstruction is present.

Each tablet contains Bethacol 25 mg as the active pharmaceutical ingredient, commonly available in strengths such as 10 mg, 25 mg, and 50 mg, along with standard pharmaceutical excipients (diluents, binders, disintegrants, and lubricants) used to formulate the tablet.

Bethacol 25 mg is a synthetic ester of choline and a direct-acting cholinergic (parasympathomimetic) agent. Unlike acetylcholine, Bethacol 25 mg is structurally resistant to hydrolysis by acetylcholinesterase, which gives it a longer duration of action and relatively selective muscarinic (rather than nicotinic) activity.

Bethacol 25 mg is used clinically to restore detrusor muscle tone and promote bladder emptying in patients with non-obstructive urinary retention.

Cholinergic Agonist (Parasympathomimetic) – Urinary Cholinergic Agent; Bethacol 25 mg belongs to this class.

Bethacol 25 mg is a direct-acting cholinergic agonist that selectively stimulates muscarinic receptors with minimal nicotinic activity, and is largely resistant to breakdown by cholinesterase enzymes, giving it a more predictable and prolonged effect compared to acetylcholine.

Mechanism of action: By stimulating muscarinic receptors on the detrusor muscle of the bladder, Bethacol 25 mg increases detrusor tone and contraction while promoting coordinated relaxation of the trigone and external sphincter, resulting in more complete bladder emptying. It also increases gastrointestinal smooth muscle tone and peristalsis, gastric motility, and salivary and gastric secretions.

Onset and duration: After oral administration, effects typically begin within 30–90 minutes and may last up to 6 hours.

Bethacol 25 mg is administered orally only, on an empty stomach (1 hour before or 2 hours after meals) to minimize gastrointestinal side effects. It must not be given by intramuscular or intravenous injection under any circumstance.

• Other cholinergic agents (e.g., cholinesterase inhibitors such as neostigmine or pyridostigmine): Concurrent use with Bethacol 25 mg can produce additive cholinergic effects (excessive salivation, bradycardia, hypotension, GI cramping); concomitant use is generally avoided.
• Ganglionic blocking agents (e.g., mecamylamine): Bethacol 25 mg may cause a critical and sudden fall in blood pressure, usually with severe abdominal symptoms, when given with ganglionic blocking agents; this combination should be avoided.
• Anticholinergic/antimuscarinic drugs (e.g., atropine): These agents pharmacologically antagonize the effects of Bethacol 25 mg; atropine is in fact used as the antidote for Bethacol 25 mg overdose (see Overdose).
• Drugs that may unmask or worsen cholinergic sensitivity (e.g., in patients with asthma or cardiac disease) should be used cautiously together with Bethacol 25 mg (see Precautions and Warnings).

Side effects of Bethacol 25 mg are generally dose-related, resulting from its cholinergic activity, and often improve with dose adjustment. Common and important effects include:

• Excessive salivation, sweating, and flushing (feeling of warmth)
• Abdominal cramping/discomfort, nausea, vomiting, diarrhea, borborygmi (increased bowel sounds)
• Urinary urgency
• Headache and malaise
• Hypotension, reflex tachycardia, or bradycardia
• Blurred vision and miosis (pupil constriction)
• Bronchospasm or asthmatic attack (uncommon, more likely in susceptible individuals — see Contraindications)

Patients should report severe or persistent side effects to their physician promptly.

Pregnancy: Adequate, well-controlled studies of Bethacol 25 mg in pregnant women are lacking. Bethacol 25 mg should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

Lactation: It is not well established whether Bethacol 25 mg passes into human breast milk. Because of the potential for cholinergic effects in a nursing infant, Bethacol 25 mg should be used during breastfeeding only under medical advice, weighing the benefits of treatment against potential risk to the infant.

• Route of administration: Bethacol 25 mg must not be given by intramuscular or intravenous injection — severe cholinergic reactions, including profound hypotension, shock, and cardiac arrest, have been associated with parenteral use outside the approved oral route. Strict adherence to the approved oral route and dosing is essential.
• Respiratory disease: Use with caution in patients with any respiratory disease, even without a formal diagnosis of asthma, due to the risk of bronchospasm (active bronchial asthma is an absolute contraindication — see Contraindications).
• Cardiovascular effects: Bethacol 25 mg can cause bradycardia and hypotension through its cholinergic action; use with particular caution in patients with underlying cardiovascular disease.
• Cholinergic side effects: Excessive salivation, sweating, flushing, abdominal cramping, diarrhea, and urinary urgency are dose-related and often improve with dose reduction (see Side Effects).
• Antidote availability: Atropine should be readily available as a specific antidote in case of a cholinergic (muscarinic) overdose or excessive response to Bethacol 25 mg.
• Use with caution in elderly patients and in those with a history of epilepsy or Parkinsonism, as cholinergic stimulation may aggravate these conditions.

Overdose of Bethacol 25 mg produces signs of cholinergic (muscarinic) excess, including excessive salivation, sweating, flushing, abdominal cramps, nausea, vomiting, diarrhea, involuntary defecation or urination, bronchospasm, marked bradycardia, hypotension, and, in severe cases, cardiovascular collapse.

In case of suspected overdose, seek immediate medical attention or contact emergency services/poison control. Atropine is the specific antidote and should be administered by a healthcare professional as needed, along with supportive care (e.g., airway management, cardiovascular support) in a medical facility. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Use Bethacol 25 mg with caution; start at the lower end of the dosing range and monitor closely for cardiovascular and cholinergic side effects.
• Renal impairment: No well-established formal dose adjustment; use with caution and monitor for excessive cholinergic effects.
• Hepatic impairment: No well-established formal dose adjustment; use with caution.
• Pediatric patients: Safety and efficacy have not been established (see Pediatric Uses).
• Cardiac, respiratory, or GI disease: See Contraindications and Precautions and Warnings, as several of these conditions are absolute contraindications to Bethacol 25 mg.

Duration of treatment with Bethacol 25 mg is individualized by the treating physician based on clinical response. For postoperative or postpartum non-obstructive urinary retention, treatment is typically short-term, continued only until normal voiding function is restored. For chronic neurogenic bladder atony, Bethacol 25 mg may be used longer-term under close medical supervision, with periodic reassessment of continued need and tolerability.

Cholinergic agonist; Parasympathomimetic; Urinary cholinergic agent

Bethacol 25 mg is a direct-acting muscarinic cholinergic agonist. Structural modification of the choline ester renders Bethacol 25 mg resistant to hydrolysis by acetylcholinesterase, unlike endogenous acetylcholine, allowing it to act more selectively and for a longer duration at muscarinic receptors with minimal nicotinic (ganglionic) activity. Stimulation of muscarinic receptors on bladder detrusor smooth muscle increases contractility and tone, while promoting coordinated sphincter relaxation, thereby facilitating bladder emptying. It similarly increases gastrointestinal smooth muscle tone and peristaltic activity.

C

The safety and efficacy of Bethacol 25 mg have not been established in pediatric patients. Use in children should be undertaken only under specialist supervision when a physician determines the potential benefit justifies the potential risk, with close monitoring for cholinergic side effects.